Table 3. Changes in IMT from baseline at 104 weeks in patients treated with or without sitagliptin in subgroup analysis based on the occurrence of hypoglycemia.
| Parameters | Hypoglycemia | Sitagliptin group | Conventional group | P value |
|---|---|---|---|---|
| Change in mean IMT-CCA | No | −0.057 ± 0.140 (n = 72)§ | 0.012 ± 0.138 (n = 73) | 0.003 |
| Yes | 0.012 ± 0.201 (n = 49) | 0.042 ± 0.135 (n = 49)* | 0.38 | |
| Change in right max IMT-CCA | No | −0.039 ± 0.243 (n = 72) | 0.041 ± 0.412 (n = 73) | 0.16 |
| Yes | 0.062 ± 0.470 (n = 48) | −0.007 ± 0.295 (n = 49) | 0.39 | |
| Change in left max IMT-CCA | No | −0.105 ± 0.298 (n = 72)# | −0.003 ± 0.304 (n = 73) | 0.042 |
| Yes | −0.005 ± 0.393 (n = 49) | 0.060 ± 0.266 (n = 49) | 0.34 |
Data are mean ± SD. Differences in parameters from baseline to 104 weeks within group were analyzed by one-sample t-test. Differences in parameters from baseline to 104 weeks between groups were analyzed by the Student’s t-test. *P < 0.05, #P < 0.01, §P < 0.001.